Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.05 - $36.33
Previous CloseN/A
Volume726.99K
Average Volume (3M)4.58M
Market Cap
$20.35B
Enterprise Value$22.71B
Total Cash (Recent Filing)$1.82B
Total Debt (Recent Filing)$7.62B
Price to Earnings (P/E)14.8
Beta0.32
Next Earnings
Aug 06, 2025EPS Estimate
1.04Last Dividend Ex-Date
May 16, 2025Dividend Yield2.43%
Share Statistics
EPS (TTM)0.41
Shares Outstanding421,370,670
10 Day Avg. Volume4,284,798
30 Day Avg. Volume4,576,594
Financial Highlights & Ratios
PEG Ratio-4.42
Price to Book (P/B)3.08
Price to Sales (P/S)0.00
P/FCF Ratio4.14
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit10.07
Enterprise Value/Ebitda2.93
Forecast
1Y Price Target
$43.75Price Target Upside20.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Royalty Pharma News
See All RPRX News
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe transaction sets Royalty Pharma on track to meet or exceed its 5-year capital deployment target, demonstrating confidence in their strategic direction.
Regulatory ApprovalsFDA has granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC in patients with KRAS G12 mutations.
Royalty Financing DealThe announced royalty financing deal with Revolution Medicines allows Royalty Pharma to participate in the upside of the target asset daraxonrasib for oncology.
Bears Say
Management StrategyThe move to internalize the manager simplifies financial reporting and provides clear alignment between management and shareholders, but it might disrupt current operations.
Market CompetitionTremfya should fight Skyrizi to a draw in ulcerative colitis, and RPRX garners a tiered mid-single digit royalty on Tremfya through 2031-32.
Pipeline ChallengesThe company's growth profile is above the peer average, yet the lack of an internal pipeline could pose challenges to adapting to potential changes in the regulatory environment.
Ownership Overview
1.86% Insiders
19.91% Mutual Funds
18.11% Other Institutional Investors
43.16% Public Companies and Individual Investors
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $36.33 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $20.35B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Aug 06, 2025 which is in 32 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on May 08, 2025. The company reported $0.412 earnings per share for the quarter, missing the consensus estimate of $0.953 by -$0.541.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.856 which represents an annual dividend yield of 2.43%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.04.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 421,370,670 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $0.412 in its last earnings report, missing expectations of $0.953. Following the earnings report the stock price went up 1.076%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.75 (20.89% Upside)
$43.75 (20.89% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.98%
12-Months-Change
Fundamentals
Return on Equity
16.57%
Trailing 12-Months
Asset Growth
9.16%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Company Deck
RPRX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Royalty Pharma's strong financial performance, dynamic capital allocation strategy, and significant portfolio expansions, alongside some concerns about policy uncertainties and ongoing disputes. The company remains optimistic about its future growth and market opportunities.Read More>RPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$43.75
▲(20.89%Upside)